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Crystalluria: A clinically useful investigation in children with primary
hyperoxaluria post-transplantation. Technical Note. Primary hyperoxalu-
ria type I (PH I) is a congenital error of metabolism that can be manifested
by an increased oxalate production, and ultimately result in kidney failure.
After a combined liver/kidney transplantation, children with PH I have
persistant excretion of oxalate that causes crystal formation in the urinary
tract, and could result in systemic oxalosis and eventual graft failure. We
speculated that crystalluria may be predictive of this nephrolithogenic
tendency and thus investigated the effect of an intensive therapeutic
strategy to prevent crystal formation in 13 children at our hospital. Oxalate
crystal volume (OCV) measurements were performed at regular intervals
for 36 months, and compared with urine supersaturation measurements.
We found that crystalluria with the OCV measurement is non-invasive,
easily performed, and gives feedback on the efficacy of PH I therapy
within one hour. Further study is needed to determine whether this
method is a better predictor of nephrocalcinosis than is supersaturation
alone.
Primary hyperoxaluria type I (PH I) is a rare autosomal
recessive inborn error of metabolism caused by a deficiency of the
liver-specific peroxisomal enzyme alanine:glyoxylate aminotrans-
ferase [1]. It is manifest by increased oxalate production that
ultimately results in kidney failure, due to urolithiasis, nephrocal-
cinosis and infection. When the glomerular filtration rate (GFR)
falls below 30 to 40 ml/min/1.73 m2, oxalate accumulates resulting
in deposition of oxalate crystals in muscle, bone, the vasculature
and nerve tissue (systemic oxalosis). In established end-stage renal
failure, hemodialysis does not adequately remove the excess
oxalate [2] and renal transplantation alone offers only a tempo-
rary solution, with early failure of the graft due to oxalate
deposition being the commonest outcome (3-year graft survival
rate between 17 and 45% in cadaveric grafts) [3, 4]. Combined
liver/kidney transplantation, introduced by Watts et al [5], is
performed by many European centers to normalize oxalate me-
tabolism (2-year graft survival of 78% on 61 patients) [6]. Com-
bined liver/kidney transplantation in children with PH I is consid-
ered when GFR is below 20 ml/min/1.73 m2 to limit systemic
oxalosis. This approach corrects the metabolic defect, however,
these children have important oxalate stores that are slowly
released causing persistent urine oxalate excretion for months or
years following transplantation [7]. Post-transplant management
should include strategies to prevent crystal formation in the
urinary tract [8]. To date supersaturation, urine and plasma
oxalate levels have been used to titrate treatment accordingly [9].
It has been proposed that crystalluria may be predictive of a
nephrolithogenic tendency [10]. We have therefore investigated
the effect of an intensive therapeutic strategy to prevent crystal
formation on urinary crystal excretion assessed by crystalluria in
children with primary hyperoxaluria post-transplantation. We also
have compared crystalluria to urine supersaturation and 24-hour
urinary oxalate excretion in this indication.
METHODS
Patients
Two groups of patients were studied between April 1990 and
June 1996. The first group of seven children in end-stage renal
failure underwent liver/kidney transplantation for PH I at the
Hoˆpital Necker-Enfants Malades in Paris. All required full renal
replacement therapy prior to grafting. One child died within four
days of transplantation, from hepatic artery thrombosis. Six
patients showed an immediate clinical and biochemical satisfac-
tory post-transplant course. Post-transplantation management
included quadruple sequential immunosuppression and prophy-
lactic measures to prevent nephrocalcinosis [7]. This consisted of
hemodialysis, forced diuresis ($ 2.5 l/m2/24 hr, with frusemide)
and magnesium sulfate 0.3 mmol/kg/24 hours, in patient 1.
Hemodialysis was not used for the remaining children (see below)
who were managed with diuretics (thiazides) and sodium citrate
according to the level of crystalluria.
A second group of six children with PH I, mean age 8.5 years
old (range from 2- to 15-years-old) was also studied during the
same period. These patients did not require renal replacement
therapy and were treated conservatively with a high daily water
intake (Þ 2 liter/m2/24 hr), crystallization inhibitors (sodium
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citrate, orthophosphate) and pyridoxine. Urinary samples for this
group were collected either during acute hospitalization in our
pediatric nephrology unit or at out-patient follow-up.
Biochemical and crystalluria assessments
Serum creatinine and oxalate concentration, urine oxalate
excretion and crystalluria with measurement of oxalate crystal
volume (OCV) were performed at least daily the first 10 days after
transplantation. After this period or in the group with conserva-
tive treatment, crystalluria was assessed at an out-patient fol-
low-up on a random urine sample.
Crystalluria was assessed on a fresh urine sample, from an
urethral catheter during the first ten days after grafting within
thirty minutes following collection. Samples were transferred to a
Malassez cell and examined under a polarizing microscope to
determine the types of crystals, their size and number.
Urinary pH was measured and biochemical determinations of
creatinine, calcium, magnesium, phosphate, urate, urea, sodium,
potassium and chloride performed on a multiparametric analyzer
Hitachi 717 (Boehringer, Mannheim, Germany). Oxalate and
citrate were measured by enzymatic methods (oxalate, Biorea,
Talant, France; citrate, Boehringer). Urinary supersaturation was
calculated using the software EQUIL V5 (updated version of
EQUIL 2) [11].
Calculation of oxalate crystal volume
There is a large variation of crystals size in urine of patients
with hyperoxaluria. Thus, we did not use the number of crystals as
an indicator of oxalate crystal volume (OCV), but we calculated
this OCV using the following technique.
Calcium oxalate crystals were counted separately in urine as
monohydrate (COM) or dihydrate (COD) phases. For each
crystal, the size (in micrometers) according to their geometric
structure was measured using a graduated scale in the ocular lens:
L for COM and a-b-d for COD (Fig. 1 and below). Crystal oxalate
monohydrate and COD volumes were calculated as the product of
mean crystal volume based on morphology and size by the number
of crystals per mm3 of urine.
We determined the mean size for each morphology from twenty
consecutive crystals found in the Malassez cell. When less than
twenty crystals were present all were included in the measure-
ment. The overall crystal volume was determined by adding both
COM and COD crystal volumes.
The volume for each crystal species was mathematically calcu-
lated from the geometric structure and size of the crystals. For
COM crystals, which resemble erythrocytes (Fig. 1), the volume
was calculated by the relation:
VCOM 5 0.19 3 L
3
where L was the length of the crystal.
In contrast, COD crystals may be either octahedral or dodeca-
hedral, as a result three forms of crystals were quantified accord-
ing to the length (b) developed between the two pyramids (Fig. 1).
The first crystal volume calculation, corresponding to octahedral
morphology (b 5 0), was:
V1 5 0.082 3 d3
where d was the length of the diagonal of the pyramid base.
For dodecahedral crystals (b . 0), two equations were used.
One, when the length between the two pyramids was about one
fourth of pyramid base height (a):
V2 5 0.17 3 d3
This equation corresponded to V2 5 0.088 3 d3 1 V1.
The second equation was applied to crystals with higher value
of b, for instance a/4 , b , 1.5 3 a, corresponding to an extended
growth of the intermediate faces between pyramids:
V3 5 0.5 3 d3
The latter relation was rarely used because the corresponding
COD morphology is usually observed with very high urinary
calcium levels.
The VCOM, V1, V2, V3, and COD volume (VCOD 5 V1 1 V2
1 V3) were automatically calculated from the crystal number and
sizes (L, a, b and d) by a simple computer program.
We then calculated the oxalate crystal volume (OCV) in
mm3/mm3 as the sum of VCOM 1 VCOD.
Statistical methods
The relationship between urinary supersaturation and oxalate
crystal volume was analyzed by linear regression using an indica-
tor (or dummy) to account for multiple measures within individual
subjects and inter-individual variability. This allowed the slope of
the relationship with 95% confidence limits to be determined, and
the root mean square error of the regression matrix allowed the
calculation of the intra-individual SD of oxalate crystal volume
measurements, having accounted for variance that could be
explained by alterations in supersaturation.
RESULTS
Patient 1, who experienced increased serum creatinine concen-
tration and reduced urine output following hemodialysis, was
treated with frusemide (Fig. 2). On day 4 urinary catheter
obstruction occurred due to calcium oxalate deposition. Crystal-
luria was very high with OCV 5 34 000 m3/mm3; urinary calcium
and oxalate concentrations were 8.4 mM and 0.65 mM, respec-
tively, and at this point, hemodialysis was stopped. On day 7, OCV
Fig. 1. Diagrams of the two types of calcium oxalate crystals in urine of
children with hyperoxaluria type I in the monohydrate (A) and dihydrate
(B) phases. a, b, d and L are the parameters used to calculate oxalate
crystal volume, and are defined in the Methods section.
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was 200 m3/mm3 with 5 liter/m2/24 hr and forced diuresis; urinary
calcium and oxalate concentrations were 1 mM and 0.45 mM,
respectively. Hemodialysis was omitted from our post-transplan-
tation therapeutic strategy based on the following arguments: (1)
the large decrease in OCV observed between day 4 and day 7, (2)
the low serum concentration of oxalate between day 1 and day 10
(Table 1), and (3) the absence of a recurrent increase of creatinine
concentration after cessation of hemodialysis. Urine output, OCV
and creatinine clearance for five patients within the first 10 days
after combined liver and kidney transplantation are shown in
Table 1. The OCVs were much lower in this group when
compared to the group with conservative treatment [230 6 540
(N 5 33) and 17260 6 35190 (N 5 21) respectively], despite
similar oxalate urine concentrations (1.25 6 0.87 mM and 1.24 6
0.88 mM).
On post-operative day 10, patient 2 developed sepsis with a
resulting fall in urine output (, 1 liter/m2/24 hr). This was
associated with a raised OCV of 2900 mm3/mm3. The reduced
urine output in conjunction with increased OCV in the setting of
proven sepsis prompted treatment with colloid infusion, an in-
crease of fluid intake without the use of frusemide and the use of
appropriate antimicrobial therapy.
On day 4, patient 4 had a sudden OCV increase to 800
mm3/mm3, despite a urine output over 4 liter/m2/24 hr. This
increase was immediatly treated with hydrochlorothiazide (2
mg/kg/24 hr) and sodium citrate. Twenty-four hours later OCV
was 450 mm3/mm3. This acute increase was later attributed to an
increased urinary oxalate excretion (1.41 to 2.37 mmol/24 hr).
In patient 5, an increase in OCV at day 5 despite a stable urine
output of 2.9 liter/m2/24 hours was observed. Thiazide was added
the same day and OCV decreased within 24 hours from 877 to 130
mm3/mm3. This high OCV at day 5 was attributed 24 hours later
to an increase of urinary calcium excretion (3.9 mmol/liter), with
a stable 24-hour urinary oxalate excretion (3 mmol/24 hr).
Oxalate crystal volume measurements were performed at 1, 3,
6, 12, 18, 24 and 36 months after transplantation. The values
(mean 6 SD) were 413 6 895 m3/mm3 at one month (N 5 5), 7 6
13 m3/mm3 at three months (N 5 6), 116 6 172 m3/mm3 at six
months (N 5 4), 10 6 20 m3/mm3 at 12 months (N 5 4), 82 6 140
m3/mm3 at 18 months (N 5 3), 1 6 1 m3/mm3 at 24 months (N 5
3), and 21 6 26 m3/mm3 at 36 months (N 5 3). The increase in
mean OCV at six months was due to high OCV values (195 and
385 m3/mm3, respectively) in patients 2 and 3 that were not
associated with elevated urinary oxalate concentration (341 and
524 mM, respectively). No urolithiasis or nephrocalcinosis were
observed on abdominal ultrasonography. The final serum creati-
nine concentration, OCV and urine oxalate/creatinine ratio are
shown in Table 2.
Oxalate crystal volume values of the first 10 days after trans-
plantation according to supersaturation measurements are shown
in Figure 3. In 19 urine samples with supersaturation , 6, crystals
were observed (mean OCV 5 135 m3/mm3, range: 1 to 2120
Fig. 2. Effect of hemodialysis and frusemide on
serum creatinine level, daily urine output and
oxalate crystal volume evolution in a 41⁄2-year-
old girl after liver/kidney transplantation for
primary hyperoxaluria type I. Symbols are: (F)
creatinine serum level (mM); (M) urine output
(liter/m2/24 hr), f hemodialysis session, (3
frusemide administration, (b) oxalate crystal
volume, value in brackets (mm3/mm3).
Table 1. Characteristics of children with primary hyperoxaluria type I and their urine output, oxalate crystal volume (OCV), creatinine clearance at
























Years D5 D10 Mean (D1 to 10) Mean 6 SD (D1 to 10)
1 F 2 4 1/3 4 1/2 — ND/6.0 ND/3.3 —/3.8 77 34.5 6 14.1 0.75 6 0.22
2 M 1/4 1/4 1 B 1 R 110/1.9 2900/0.9 1430/2.5 158 30.3 6 4.4 1.84 6 1.22
3 F 1/2 1/4 2 B 1 R 14/2.8 14/3.0 20/3.3 175 23.7 6 4.4 1.01 6 0.09
4 M 3 2/3 7 10 1/2 B 1 R 450/4.6 10/2.6 260/3.0 104 21.4 6 9.9 2.03 6 0.75
5 F 6 15 1/3 15 2/3 — 877/2.9 64/3.2 190/3.4 110 33.7 6 20.3 3.67 6 0.99
6 F 12 12 13 — 30/8.9 12/3.0 25/5.0 96 16.8 6 4.7 2.93 6 1.54
Abbreviations are: D1, D5, D10, days 1, 5 and 10 after LKT; F, female; M, male; B, bone; R, retina; ND, not done.
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m3/mm3). Linear regression analysis of the whole values showed a
significant relation between the two variables. The equation of the
relation was: OCV 5 (596 3 supersaturation value) 22985 (P ,
0.0001). The 95% confidence limits for the slope of this relation
were 380 to 911. The intra-individual SD of measurements of
oxalate crystal volume within subjects was 6920 mm3/mm3. There
was no correlation either between OCV and 24 hours urine
output, or between OCV and 24-hour urinary oxalate excretion
(P . 0.05).
DISCUSSION
Crystalluria with oxalate crystal volume measurement is nonin-
vasive, easily performed, and gives information within one hour
on the efficiency of prophylaxis against oxalate crystal formation
in primary hyperoxaluria type I after liver/kidney transplantation.
Crystalluria reflects the presence or absence of crystals in urine
and, when regularly performed, can be a quantitative guide to
adequacy of prophylaxis. Post-operative monitoring in trans-
planted children with hyperoxaluria type I was based on crystal-
luria for the following reasons: it is noninvasive, easily performed,
and measurements are rapidly available. To simplify the interpre-
tation of crystalluria, oxalate crystal volume was calculated from
the geometric structure and size of the crystals was used to assess
the total urinary amount. As expected, the maximum prophylactic
treatment comprising forced diuresis by supraphysiological daily
fluid maintenance, crystal formation inhibitors and thiazides after
transplantation results in very low levels of crystalluria when
compared to the conservative treatment group (230 6 540 m3/
mm3 and 17260 6 35190 m3/mm3, respectively).
This method of determining urinary crystal load has been used
effectively in our hands in routine patient management. In patient
1, hemodialysis was stopped when we observed large amount of
crystals in urine with an increasing serum creatinine concentration
and difficulty in maintaining the desired urine output (. 2
liter/m2/24 hr). The ability of hemodialysis to remove oxalate was
limited by low serum oxalate concentration and was associated
with a marked plasma creatinine concentration increase following
each session (Fig. 2). The reasons for this observation are unclear,
and possible explanations include impaired graft perfusion during
hemodialysis, and oxalate crystal deposition secondary to oliguria
and hypercalciuria induced by frusemide. For the next five
children with normal serum creatinine levels, this treatment
regimen obviated the need for post-transplant hemodialysis. As
fluid and electrolyte balance control is difficult when high urine
output is required in post-operative children, our strategy was to
obtain a daily urine output of 3 liter/m2/24 hr and an OCV below
100 m3/mm3. This strategy was well tolerated with normal renal
function at day 10 (Table 1) and reduced the potential hazards of
large intravenous fluid intakes.
Levels of crystalluria were also determined regularly following
discharge from hospital and there were no large variations as
compared to early post-transplantation findings.
In this study, there were marked differences in supersaturation
levels after transplantation, probably a result of variable oxalate
and calcium concentration. Spontaneous crystal formation in
urine is determined by the supersaturation of solute. A supersat-
uration below 6 will not result in crystal formation in less than a
month [12]. Our findings of urine crystals with a supersaturation
below 6 in the first 10 days after liver and kidney transplantation
can be explained by intra-renal crystal formation where supersat-
uration was high and crystals were later released into the urinary
tract. With such a hypothesis, crystalluria may not only be an
indicator of crystal formation risk in lower urinary tract but also
reflects what is happening within the kidney, and thus supersatu-
ration alone is not an effective predictor of intrarenal crystal
formation.
Serum oxalate concentrations are not helpful in assessing the
risk of crystal formation as they all fell in normal range from day
1 post-transplant. A normal 24-hr urinary oxalate excretion can be
expected when body stores are depleted [9]. Using 24-hr urinary
oxalate excretion measurements to direct the management of
post-operative prophylaxis is of limited value for the following
reasons: (1) in intensive care, prophylaxis should be instituted
rapidly in at risk children and the delay associated with a
prolonged collection and quantification is unacceptable; (2) in
Fig. 3. Oxalate crystal volume values according to supersaturation mea-
surements the first 10 days after combined liver/kidney transplantation in
six chidren with hyperoxaluria type I. Supersaturation was calculated
using the EQUIL V5 program. The dashed line is the regression line
between urinary supersaturation and oxalate crystal volume [OCV 5
(596 3 supersaturation value) 22985; P , 0.0001].
Table 2. Final serum creatinine concentration, oxalate crystal volume
(OCV), urine oxalate/creatinine concentration ratio of 6 children with














1 76 77 0 0.044
2 67 74 0 0.063
3 37 62 0 0.104
4 21 79 243 0.213
5 6 97 4 0.050
6 5 115 0 0.044
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long-term management, it is sometimes difficult to collect 24-hr
urine output in children. For this last reason urine oxalate/
creatinine ratio and crystalluria with OCV measurement on a
fresh urine sample have been proposed as simpler indicators [7].
In conclusion, crystalluria with oxalate crystal volume measure-
ment is simple, noninvasive, rapidly and easily performed and has
been used effectively in the management of prophylactic treat-
ment in primary hyperoxaluria type I after liver/kidney transplan-
tation. This measurement could be a predictor of both lower
urinary tract and even intrarenal events. Further study may
demonstrate that it is a better predictor of nephrocalcinosis than
is supersaturation alone.
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